TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian & Breast Cancer
September 16 2014 - 8:30AM
Business Wire
All Patients Developed Immune Responses as All
Five Peptides Shown to be Immunogenic
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that
analysis of the interim data from the first 13 patients in a Phase
I clinical trial show that each of the patients treated have raised
specific T-cell immune responses against a set of 5 naturally
processed folate receptor alpha Class II antigenic epitopes. All
five of the constituent peptides were found to be immunogenic and
all patients developed immune responses to at least one and in most
cases more than one of the vaccine peptides.
The trial is fully accrued and as of August 26, 2014, all 22
patients had completed their vaccinations. Eight women with
HER2-negative breast cancer, thirteen with ovarian cancer and one
with fallopian tube cancer were enrolled. Glynn Wilson, TapImmune’s
CEO stated “In general, the vaccine has been well tolerated. This
is the first positive endpoint we have reported for the clinical
study on folate receptor alpha antigens and when taken together,
the promising data on safety and immune responses are tremendously
encouraging and provide a clear scientific rationale for
progressing to a Phase II Clinical Trial. In addition to the
primary Ovarian indication, this set of antigens and our approach
fills a significant need for treatments for difficult to treat
cancers for which targeted therapies are not available, for example
Triple-negative breast cancer.”
The Phase I trial is being carried out at the Mayo Clinic,
Rochester, MN. TapImmune has an Exclusive Option to License this
antigen technology.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the
development of innovative vaccine technologies for the treatment of
cancer and infectious disease. The Company’s vaccine compositions,
peptide or nucleic acid-based, comprise one or multiple naturally
processed epitopes (NPEs) designed to comprehensively stimulate a
patient’s killer T-cells and helper T-cells and to restore or
further augment antigen presentation by the modulation of TAP
(Transporter associated with
Antigen Processing). The Company believes that its vaccine
compositions may be used as stand-alone medications or in
combination with current treatment modalities. Please visit the
Company’s website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer: This release
contains forward-looking information within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this news release concerning the Company’s expectations, plans,
business outlook or future performance, and any other statements
concerning assumptions made or expectations as to any future
events, conditions, performance or other matters, are
“forward-looking statements”. Forward-looking statements are by
their nature subject to risks, uncertainties and other factors
which could cause actual results to differ materially from those
stored in such statements. Such risks, uncertainties and factors
include, but are not limited to the risks set forth in the
Company’s most recent Form 10-K and other SEC filings which are
available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements
TapImmune Inc.Glynn Wilson, PH.D., 866-359-7541Chairman &
CEOorInvestor RelationsJ.Streicher Capital, LLC.Robert
Giordano, 212-257-5495rgiordano@jstreichercapital.com
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From May 2024 to Jun 2024
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Jun 2023 to Jun 2024